Current and future drug targets in weight management

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 1792-1818

  Witkamp, Renger F ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

energy metabolism; food intake; obesity complications; satiety hormones; weight management

Indexed keywords

189075; 2,4 DINITROPHENOL; AMFEBUTAMONE; ANTIOBESITY AGENT; BOMBESIN; CANAGLIFLOZIN; CANAGLIFOZIN; CETILISTAT; CHOLECYSTOKININ; DEXFENFLURAMINE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIRLOTAPIDE; EGR 773; ENZYME INHIBITOR; EPHEDRINE; FENFLURAMINE; GSK 869682; LOMITAPIDE; LORCASERIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NALTREXONE; PF 04620110; PHENTERMINE; PLACEBO; REMOGLIFOZIN ETABONATE; RIMONABANT; SERGLIFOZIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; USISTAPIDE;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; DIET RESTRICTION; DRUG APPROVAL; DRUG BINDING SITE; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENERGY ABSORPTION; ENERGY EXPENDITURE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FLORA; LIPID ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SATIETY; SIDE EFFECT; STEATORRHEA; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; OBESITY;

EID: 79961165599     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0341-1     Document Type: Review

References (174)

1. DH Bessesen 2008 Update on obesity J Clin Endocrinol Metab 93 2027 2034 18539769 1:CAS:528:DC%2BD1cXntFamsLY%3D (Pubitemid 351831511)
2. WPT James 2008 The epidemiology of obesity: the size of the problem J Intern Med 263 336 352 18312311 1:STN:280:DC%2BD1c7msFaltg%3D%3D (Pubitemid 351342683)
3. Y Wang MA Beydoun L Liang B Caballero SK Kumanyika 2008 Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic Obesity 16 2323 2330 18719634
4. J-P Despres I Lemieux 2006 Abdominal obesity and metabolic syndrome Nature 444 881 887 17167477 1:CAS:528:DC%2BD28XhtlShtrzF (Pubitemid 46024995)
5. SM Grundy JI Cleeman SR Daniels, et al. 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 112 2735 2752 16157765 (Pubitemid 41532612)
6. DW Haslam WP James 2005 Obesity Lancet 366 1197 1209 16198769 (Pubitemid 41393598)
7. CS Fox JM Massaro U Hoffmann, et al. 2007 Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the framingham heart study Circulation 116 39 48 17576866 (Pubitemid 47016245)
8. JL Kuk PT Katzmarzyk MZ Nichaman TS Church SN Blair R Ross 2006 Visceral fat is an independent predictor of all-cause mortality in men Obesity 14 336 341 16571861 (Pubitemid 46214766)
9. A Behn E Ur 2006 The obesity epidemic and its cardiovascular consequences Curr Opin Cardiol 21 353 360 16755205 (Pubitemid 44315069)
10. TS Han N Sattar M Lean 2006 Assessment of obesity and its clinical implications Br Med J 333 695 698 (Pubitemid 44521018)
11. G O'Donovan EL Thomas JP McCarthy, et al. 2009 Fat distribution in men of different waist girth, fitness level and exercise habit Int J Obes 33 1356 1362
12. A Romero-Corral VK Somers J Sierra-Johnson, et al. 2010 Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality Eur Heart J 31 737 746 19933515
13. GS Hotamisligil 2006 Inflammation and metabolic disorders Nature 444 860 867 17167474 1:CAS:528:DC%2BD28XhtlShtrzK (Pubitemid 46024993)
14. SE Shoelson L Herrero A Naaz 2007 Obesity, inflammation, and insulin resistance Gastroenterology 132 2169 2180 17498510 1:CAS:528: DC%2BD2sXmsVyns7w%3D (Pubitemid 46693756)
15. A Guilherme JV Virbasius V Puri MP Czech 2008 Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes Nat Rev Mol Cell Biol 9 367 377 18401346 1:CAS:528:DC%2BD1cXkvF2gt7k%3D (Pubitemid 351574198)
16. S Mittra VS Bansal PK Bhatnagar 2008 From a glucocentric to a lipocentric approach towards metabolic syndrome Drug Discov Today 13 211 218 18342796 1:CAS:528:DC%2BD1cXjsVSjsbs%3D
17. A Fleischman SE Shoelson R Bernier AB Goldfine 2008 Salsalate improves glycemia and inflammatory parameters in obese young adults Diab Care 31 289 294 1:CAS:528:DC%2BD1cXis1ajsr0%3D (Pubitemid 351213338)
18. GS Hotamisligil E Erbay 2008 Nutrient sensing and inflammation in metabolic diseases Nat Rev Immunol 8 923 934 19029988 1:CAS:528: DC%2BD1cXhsVWlsb7N
19. SE Shoelson AB Goldfine 2009 Getting away from glucose: fanning the flames of obesity-induced inflammation Nat Med 15 373 374 19350009 1:CAS:528:DC%2BD1MXktVKgsb0%3D
20. TP Nedungadi DJ Clegg 2009 Sexual dimorphism in body fat distribution and risk for cardiovascular diseases J Cardiovasc Transl Res 2 321 327 20560019
21. M Rebuffe-Scrive B Andersson L Olbe P Bjorntorp 1989 Metabolism of adipose tissue in intraabdominal depots of nonobese men and women Metabolism 38 453 458 2725284 1:CAS:528:DyaL1MXhslSks7k%3D (Pubitemid 19125880)
22. TM McLaughlin T Liu G Yee, et al. 2010 Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue Obesity 18 926 931 19910937 1:CAS:528:DC%2BC3cXlt1ahsbc%3D
23. Janiszewski PM, Ross R. The utility of physical activity in the management of global cardiometabolic risk. Obesity. 2009;17.
24. NA Johnson T Sachinwalla DW Walton, et al. 2009 Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss Hepatology 50 1105 1112 19637289 1:CAS:528:DC%2BD1MXhtlWlu7nK
25. R Ross AJ Bradshaw 2009 The future of obesity reduction: beyond weight loss Nat Rev Endocrinol 5 319 326 19421242
26. LJ Goodyear 2008 The exercise pill - too good to be true? N Engl J Med 359 1842 1844 18946072 1:CAS:528:DC%2BD1cXht12msr%2FN
27. J Himms-Hagen 2004 Exercise in a pill: feasibility of energy expenditure targets Curr Drug Targets CNS Neurol Disord 3 389 409 15544447 1:CAS:528:DC%2BD2cXhtVWitLnN (Pubitemid 39545297)
28. VA Narkar 2008 AMPK and PPARδ agonists are exercise mimetics Cell 134 405 415 18674809 1:CAS:528:DC%2BD1cXhtVSis77P
29. Berridge KC, Ho CY, Richard JM, DiFeliceantonio AG. The tempted brain eats: Pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010.
30. JCG Halford EJ Boyland JE Blundell TC Kirkham JA Harrold 2010 Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 6 255 269 20234354 1:CAS:528:DC%2BC3cXltV2jtbY%3D
31. DJ Mela 2006 Eating for pleasure or just wanting to eat? Reconsidering sensory hedonic responses as a driver of obesity Appetite 47 10 17 16647788 (Pubitemid 44038034)
32. RAH Adan LJMJ Vanderschuren SE la Fleur 2008 Anti-obesity drugs and neural circuits of feeding Trends Pharmacol Sci 29 208 217 18353447 1:CAS:528:DC%2BD1cXksVehsrk%3D
33. D Cota MH Tschöp TL Horvath AS Levine 2006 Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51 85 107 16364446 1:CAS:528:DC%2BD28XltFOnur0%3D (Pubitemid 43782532)
34. MJF Bult T van Dalen AF Muller 2008 Surgical treatment of obesity Eur J Endocrinol 158 135 145 18230819 1:CAS:528:DC%2BD1cXisFygur8%3D (Pubitemid 351298529)
35. J Couzin 2008 Medicine: bypassing medicine to treat diabetes Science 320 438 440 18436751 1:CAS:528:DC%2BD1cXltlCls7c%3D
36. RB Rothman MH Baumann 2009 Appetite suppressants, cardiac valve disease and combination pharmacotherapy Am J Ther 16 354 364 19092640
37. Witkamp RF. Biologically active compounds in food products and their effects on obesity and diabetes. Comprehensive natural products II. Oxford: Elsevier; 2010. p. 509-45.
38. RB Birari KK Bhutani 2007 Pancreatic lipase inhibitors from natural sources: unexplored potential Drug Discov Today 12 879 889 17933690 1:CAS:528:DC%2BD2sXhtFKit77J (Pubitemid 47539967)
39. FDA. Early communication about an ongoing safety review Orlistat (marketed as Alli and Xenical). 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm179166.
40. P Kopelman GH De Groot A Rissanen, et al. 2010 Weight loss, HbA 1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (xenical) Obesity 18 108 115 19461584 1:CAS:528:DC%2BD1MXhs1Sqt7vE
41. MM Hussain A Bakillah 2008 New approaches to target microsomal triglyceride transfer protein Curr Opin Lipidol 19 572 578 18957879 1:CAS:528:DC%2BD1cXht12gu7vM
42. L Van Gaal F Vercruysse E Wajs J Xie D Ways L van Nueten 2010 JNJ-16269110, an enterically targetted microsomal triglyceride transfer protein inhibitor, lowers body weight in overweight/obese subjects Obes Rev 11 supplement 1 43
43. HC Chen RV Farese Jr 2005 Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice Arterioscler Thromb Vasc Biol 25 482 486 15569818 1:CAS:528:DC%2BD2MXhtl2ktLc%3D (Pubitemid 40330925)
44. YG Shi D Cheng 2009 Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism Am J Physiol Endocrinol Metab 297 E10 E18 19116371 1:CAS:528:DC%2BD1MXovVKjtrw%3D
45. AstraZeneca. Pipepline summary 2010; http://www.astrazeneca.com/research/ our-pipeline-summary/. Access date August 15, 2010.
46. I Idris R Donnelly 2009 Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug Diab Obes Metab 11 79 88 1:CAS:528:DC%2BD1MXivVWjtrc%3D
47. Johnson & Johnson. Pharmaceutical pipeline - recent approvals/potential filings. Selective highlights as of 7/20/2010. http://files.shareholder.com/downloads/JNJ/990821560x0x387659/ f0fa5052-2cba-4402-91ab-b40b1fbd5e76/Q22010pipeline.pdf.
48. RE Ley PJ Turnbaugh S Klein JI Gordon 2006 Microbial ecology: human gut microbes associated with obesity Nature 444 1022 1023 17183309 1:CAS:528:DC%2BD28XhtlemtLvM (Pubitemid 46018512)
49. PJ Turnbaugh RE Ley MA Mahowald V Magrini ER Mardis JI Gordon 2006 An obesity-associated gut microbiome with increased capacity for energy harvest Nature 444 1027 1031 17183312 (Pubitemid 46018515)
50. F Thuny H Richet J-P Casalta E Angelakis G Habib D Raoult 2010 Vancomycin treatment of infective endocarditis is linked with recently acquired obesity PLoS ONE 5 e9074 20161775
51. MS Engelstoft KL Egerod B Holst TW Schwartz 2008 A gut feeling for obesity: 7TM sensors on enteroendocrine cells Cell Metab 8 447 449 19041758 1:CAS:528:DC%2BD1cXhsV2qtbjJ
52. N Delzenne J Blundell F Brouns, et al. 2010 Gastrointestinal targets of appetite regulation in humans: ILSI Supplement Obes Rev 11 234 250 20433660 1:CAS:528:DC%2BC3cXktlSmsbY%3D
53. SJ Torres CA Nowson 2007 Relationship between stress, eating behavior, and obesity Nutrition 23 887 894 17869482 (Pubitemid 47532398)
54. DE Cummings J Overduin 2007 Gastrointestinal regulation of food intake J Clin Invest 117 13 23 17200702 1:CAS:528:DC%2BD2sXmvV2rsg%3D%3D (Pubitemid 46048445)
55. S Obici 2009 Molecular targets for obesity therapy in the brain Endocrinology 150 2512 2517 19372196 1:CAS:528:DC%2BD1MXmvVCqt7o%3D
56. MT Neary RL Batterham 2009 Gut hormones: implications for the treatment of obesity Pharmacol Ther 124 44 56 19560488 1:CAS:528:DC%2BD1MXhtVegsLvM
57. KS Yan PJ Pasricha 2009 Acting in good taste: nutrient sensors in the gut Gut 58 897 898 19520884 1:CAS:528:DC%2BD1MXovFSktLs%3D
58. RL Young K Sutherland N Pezos, et al. 2009 Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes Gut 58 337 346 19039089 1:CAS:528:DC%2BD1MXjsFGgt7w%3D
59. R Yoshida T Ohkuri M Jyotaki, et al. 2010 Endocannabinoids selectively enhance sweet taste Proc Natl Acad Sci 107 935 939 20080779 1:CAS:528: DC%2BC3cXhtVyqurc%3D
60. HM Cox IR Tough A-M Woolston, et al. 2010 Peptide YY is critical for acylethanolamine receptor GPR119-induced activation of gastrointestinal mucosal responses Cell Metab 11 532 542 20519124 1:CAS:528:DC%2BC3cXnsFyit74%3D
61. DH Alpers 2010 Nutrient sensing in de gastrointestinal tract Curr Opin Gastroenterol 26 134 139 19918174
62. HS Hansen TA Diep 2009 N-acylethanolamines, anandamide and food intake Biochem Pharmacol 78 553 560 19413995 1:CAS:528:DC%2BD1MXpt1Kls70%3D
63. AA Izzo KA Sharkey 2010 Cannabinoids and the gut: new developments and emerging concepts Pharmacol Ther 126 21 38 20117132 1:CAS:528: DC%2BC3cXjt1Kgs7g%3D
64. H Lan G Vassileva A Corona, et al. 2009 GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis J Endocrinol 201 219 230 19282326 1:CAS:528: DC%2BD1MXmtlGmtr0%3D
65. LM Lauffer R Iakoubov PL Brubaker 2009 GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell Diabetes 58 1058 1066 19208912 1:CAS:528: DC%2BD1MXls1Sqs7s%3D
66. Y Yang M Chen KE Georgeson CM Harmon 2007 Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction Am J Physiol Regul Integr Comp Physiol 292 R235 R241 16902188 1:CAS:528:DC%2BD2sXisFGiur4%3D
67. HA Overton AJ Babbs SM Doel, et al. 2006 Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab 3 167 175 16517404 1:CAS:528:DC%2BD28Xislyhtr8%3D
68. Fyfe MCT, Overton HA, Procter MJ, Reynet C, White JR. Chapter 9: new nonpeptide-binding GPCRs as targets for diabetes and the metabolic syndrome. Annu Rep Med Chem. 2007;129-45.
69. HA Overton MCT Fyfe C Reynet 2008 GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity Br J Pharmacol 153 S76 S81 18037923 1:CAS:528:DC%2BD1cXislSjt7g%3D
70. Jones RM, Leonard JN, John EM. Chapter 7 the emergence of GPR119 agonists as anti-diabetic agents. Annual Reports in Medicinal Chemistry: Academic Press; 2009:149-70.
71. G Semple B Fioravanti G Pereira, et al. 2008 Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 J Med Chem 51 5172 5175 18698756 1:CAS:528:DC%2BD1cXpslahuro%3D
72. Y Wu JD Kuntz AJ Carpenter, et al. 2010 2, 5-Disubstituted pyridines as potent GPR119 agonists Bioorg Med Chem Lett 20 2577 2581 20227877 1:CAS:528:DC%2BC3cXksVGnsrk%3D
73. Arena Pharmaceuticals. APD597 for type 2 diabetes. Accessed August 20, 2010. http://www.arenapharm.com/apd597.aspx?p=2.6.
74. Metabolex. Metabolex and Sanofi-Aventis enter into an agreement for novel type2 diabetes treatment. Accessed August 10, 2010. http://www.metabolex.com/ news/jun252010.html.
75. D Cota 2008 The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity J Neuroendocrinol 20 35 38 18426497 1:CAS:528:DC%2BD1cXlsl2itbc%3D (Pubitemid 351552674)
76. V Di Marzo JP Després 2009 CB1 antagonists for obesity; what lessons have we learned from rimonabant? Nat Rev Endocrinol 5 633 638 19844251
77. PV Piazza M Lafontan J Girard 2007 Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system Diabetes Metabol 33 97 107 1:CAS:528:DC%2BD2sXmvFGkurs%3D (Pubitemid 46561389)
78. D Jones 2008 End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7 961 962 19043439 1:CAS:528: DC%2BD1cXhsVenurbO
79. FJ Bermudez-Silva MP Viveros JM McPartland F Rodriguez de Fonseca 2010 The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95 375 382 20347862 1:CAS:528: DC%2BC3cXlvVGls7w%3D
80. FJ Pavon A Serrano V Perez-Valero, et al. 2008 Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats J Neuroendocrinol 20 116 123 18426510 1:CAS:528:DC%2BD1cXlsl2iu7w%3D (Pubitemid 351552685)
81. K Sink K Segovia E Nunes, et al. 2009 Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats Psychopharmacology (Berl) 206 223 232 1:CAS:528:DC%2BD1MXot1Glsrw%3D
82. MH Son HD Kim YN Chae, et al. 2010 Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control Int J Obes 34 547 556 1:CAS:528:DC%2BC3cXjt1GntLo%3D
83. G Turu L Hunyady 2010 Signal transduction of the CB1 cannabinoid receptor J Mol Endocrinol 44 75 85 19620237 1:CAS:528:DC%2BC3cXhvFSitr0%3D
84. RZ Chen A Frassetto JZ Lao, et al. 2008 Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor Eur J Pharmacol 584 338 342 18336811 1:CAS:528:DC%2BD1cXksVaqs7o%3D
85. JM Receveur A Murray JM Linget, et al. 2010 Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier Bioorg Med Chem Lett 20 453 457 20015647 1:CAS:528:DC%2BD1MXhsF2itb7I
86. M Fridberg PB Little M Cooper NO Jensen CE Elling 2010 A single ascending dose study of TM38837-a novel second generation peripheral selective CB1 receptor antagonist in health male volunteers Obes Rev 10 supplement 1 180
87. TH Moran MJ Dailey 2009 Gut peptides: targets for antiobesity drug development? Endocrinology 150 2526 2530 19372201 1:CAS:528:DC%2BD1MXmvVCqt7g%3D
88. I Chapman B Parker S Doran, et al. 2005 Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes Diabetologia 48 838 848 15843914 1:CAS:528:DC%2BD2MXktFyhtbw%3D (Pubitemid 40767975)
89. E Ravussin 2009 Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring) 17 1736 1743 1:CAS:528:DC%2BD1MXhtVKkurnF
90. Takeda. Amylin and Takeda announce decision to advance development of Pramlintide/Metreleptin combination treatment for obesity. Accessed August 15 2010. http://www.takeda.com/press/article-35851.html.
91. RL Batterham MA Cohen SM Ellis, et al. 2003 Inhibition of food intake in obese subjects by peptide YY3-36 N Engl J Med 349 941 948 12954742 1:CAS:528:DC%2BD3sXntFeitr8%3D (Pubitemid 37064767)
92. MM Boggiano PC Chandler KD Oswald, et al. 2005 PYY3-36 as an anti-obesity drug target Obes Rev 6 307 322 16246216 1:CAS:528:DC%2BD2MXht1OlurzP (Pubitemid 41578600)
93. 7 TM Pharma. TM 30339 in gastrointestinal disorders. Accessed August 15, 2010 http://www.7tm.com/R-D/Gastrointestinal-Disorders.aspx.
94. 7TM Pharma. Information on Obinepitide. Accessed August 15 2010. http://www.7tm.com/R-D/Metabolic-Disorders/Obinepitide.aspx.
95. J Rosenthal 2010 Market watch: upcoming market catalysts in Q1 of 2010 Nat Rev Drug Discov 9 11 20043022 1:CAS:528:DC%2BD1MXhs1aqtbfJ
96. A Astrup S Rössner L Van Gaal, et al. 2009 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 1606 1616 19853906 1:CAS:528:DC%2BD1MXhtlyjtLrL
97. Novo Nordisk. Novo Nordisk is developing an oral GLP-1 to increase the convenience of GLP-1 treatment of type 2 diabetes. Accessed August 20, 2010. http://www.novonordisk.com/press/rd-pipeline/rd-pipeline.asp?showid=19.
98. R Chandra RA Liddle 2007 Cholecystokinin Curr Opin Endocrinol Diab Obes 14 63 67 1:CAS:528:DC%2BD2sXitVenu7c%3D (Pubitemid 46375391)
99. J Jordan FL Greenway LA Leiter, et al. 2008 Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients Clin Pharmacol Ther 83 281 287 17597711 1:CAS:528:DC%2BD1cXitFKjtbk%3D
100. DE Cummings JQ Purnell RS Frayo K Schmidova BE Wisse DS Weigle 2001 A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans Diabetes 50 1714 1719 11473029 1:CAS:528:DC%2BD3MXlslKnurw%3D (Pubitemid 33641587)
101. E Egecioglu E Jerlhag N Salomé, et al. 2010 Ghrelin increases intake of rewarding food in rodents Addict Biol 15 304 311 20477752 1:CAS:528:DC%2BC3cXps1ahu7s%3D
102. J Yang TJ Zhao JL Goldstein MS Brown 2008 Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides Proc Natl Acad Sci USA 105 10750 10755 18669668 1:CAS:528:DC%2BD1cXpvFOjur8%3D
103. A Moulin L Demange G Bergé, et al. 2007 Toward potent ghrelin receptor ligands based on trisubstituted 1, 2, 4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations J Med Chem 50 5790 5806 17927165 1:CAS:528:DC%2BD2sXhtFert73J (Pubitemid 350106034)
104. N Salomé C Hansson M Taube, et al. 2009 On the central mechanism underlying ghrelin's chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor antagonist J Neuroendocrinol 21 777 785 19703102
105. S Helmling C Maasch D Eulberg, et al. 2004 Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer Proc Natl Acad Sci USA 101 13174 13179 15329412 1:CAS:528:DC%2BD2cXnvFenu74%3D (Pubitemid 39209638)
106. JA Vizcarra JD Kirby SK Kim ML Galyean 2007 Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs Domest Anim Endocrinol 33 176 189 16793235 1:CAS:528: DC%2BD2sXnsFymt7k%3D (Pubitemid 47016890)
107. A Kleinridders AC Könner JC Brüning 2009 CNS-targets in control of energy and glucose homeostasis Curr Opin Pharmacol 9 794 804 19884043 1:CAS:528:DC%2BD1MXhsVGqs7jM
108. GJ Morton DE Cummings DG Baskin GS Barsh MW Schwartz 2006 Central nervous system control of food intake and body weight Nature 443 289 295 16988703 1:CAS:528:DC%2BD28Xpslalu7c%3D (Pubitemid 44435142)
109. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. NMCD. 2007;1-10.
110. LP Dwoskin AS Rauhut KA King-Pospisil MT Bardo 2006 Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent CNS Drug Rev 12 178 207 17227286 (Pubitemid 46047787)
111. MA Valentino JE Lin SA Waldman 2010 Central and peripheral molecular targets for antiobesity pharmacotherapy Clin Pharmacol Ther 87 652 662 20445536 1:STN:280:DC%2BC3czksFyjtQ%3D%3D
112. A Astrup S Madsbad L Breum TJ Jensen JP Kroustrup TM Larsen 2008 Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet 372 1906 1913 18950853 1:CAS:528:DC%2BD1cXhsVelurfO
113. Vivus Incorporated. VIVUS announces positive results from two phase 3 studies; Obese patients on Qnexa achieve average weight loss up to 14.7% and significant improvements in co-morbidities. Accessed August 10, 2010. http://ir.vivus.com/releasedetail.cfm?ReleaseID=407933.
114. KM Gadde DM Franciscy HR Wagner KR Krishnan 2003 Zonisamide for weight loss in obese adults: a randomized controlled trial JAMA 289 1820 1825 12684361 1:CAS:528:DC%2BD3sXivVSnsLg%3D (Pubitemid 37430252)
115. Orexigen. Orexigen therapeutics announces that contrave(R) reduced depression scores and body weight in overweight and obese patients with major depression. Accessed August 15, 2010. http://ir.orexigen.com/phoenix.zhtml?c= 207034&p=irol-newsArticle&ID=1441841&highlight=.
116. AS Garfield LK Heisler 2009 Pharmacological targeting of the serotonergic system for the treatment of obesity J Physiol (Lond) 587 49 60 1:CAS:528:DC%2BD1MXhtVKls70%3D
117. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia Psychopharmacology (Berl) 167 274 280 1:CAS:528:DC%2BD3sXjs1ynsL8%3D (Pubitemid 36712974)
118. 2C receptors Neuropharmacology 41 200 209 11489456 1:CAS:528:DC%2BD3MXlslersr8%3D (Pubitemid 32728091)
119. DJ Heal SL Smith A Fisas X Codony H Buschmann 2008 Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders Pharmacol Ther 117 207 231 18068807 1:CAS:528:DC%2BD1cXhtV2itrY%3D
120. SR Smith 2009 Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women Obesity (Silver Spring) 17 494 503 1:CAS:528:DC%2BD1MXit1Oiu7Y%3D
121. Arena Pharmaceuticals. Arena pharmaceuticals submits new drug application to FDA for lorcaserin for weight management. December 2009. http://invest.arenapharm.com/releases.cfm?Year=&ReleasesType=&PageNum=2.
122. 3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity Pharmacol Biochem Behav 89 499 507 18329700 1:CAS:528:DC%2BD1cXkvVOqsro%3D
123. RA Adan 2006 The MC4 receptor and control of appetite Br J Pharmacol 149 815 827 17043670 1:CAS:528:DC%2BD28Xht1ClsrjE (Pubitemid 44851706)
124. LH Van der Ploeg 2006 Design and synthesis of (ant)-agonists that alter appetite and adiposity Prog Brain Res 153 107 118 16876570
125. MK Jeon HG Cheon 2009 Promising strategies for obesity pharmacotherapy: Melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists Curr Top Med Chem 9 504 538 19689363 1:CAS:528: DC%2BD1MXhtVGntr3I
126. R Krishna B Gumbiner C Stevens, et al. 2009 Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy Clin Pharmacol Ther 86 659 666 19741604 1:CAS:528:DC%2BD1MXhsVWmu7jJ
127. JL Méndez-Andino JA Wos 2007 MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 12 972 979 17993417 (Pubitemid 350052673)
128. TA Esbenshade GB Fox MD Cowart 2006 Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders Mol Interv 6 77 88 16565470 1:CAS:528:DC%2BD28XjvVansr0%3D
129. MJ Gemkow AJ Davenport S Harich BA Ellenbroek A Cesura D Hallett 2009 The histamine H3 receptor as a therapeutic drug target for CNS disorders Drug Discov Today 14 509 515 19429511 1:CAS:528:DC%2BD1MXltlKqsr8%3D
130. R Yoshimoto Y Miyamoto K Shimamura, et al. 2006 Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus Proc Natl Acad Sci 103 13866 13871 16954192 1:CAS:528:DC%2BD28XpvFSkt74%3D (Pubitemid 44413999)
131. N Barak FL Greenway K Fujioka LJ Aronne RF Kushner 2008 Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial Int J Obes (Lond) 32 1559 1565 1:CAS:528:DC%2BD1cXht1aqsr3P
132. X-M Guan H Chen PH Dobbelaar, et al. 2010 Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity Cell Metab 11 101 112 20096642 1:CAS:528: DC%2BC3cXlsVaju7k%3D
133. R Banno D Zimmer BC De Jonghe, et al. 2010 PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice J Clin Investig 120 720 734 20160350 1:CAS:528:DC%2BC3cXjtV2ns70%3D
134. Lantz KA, Hart SGE, Planey SL, et al. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity. 2010.
135. Roitman MF, Wescott S, Cone JJ, McLane MP, Wolfe HR. MSI-1436 reduces acute food intake without affecting dopamine transporter activity. Pharmacol Biochem Behav. 2010.
136. S Tam E Saiah 2008 Recent advances in the discovery and development of PTP-1B inhibitors Drugs Future 33 175 185 1:CAS:528:DC%2BD1cXks1Gjtrc%3D (Pubitemid 351462877)
137. Y-H Tseng AM Cypess CR Kahn 2010 Cellular bioenergetics as a target for obesity therapy Nat Rev Drug Discov 9 465 482 20514071 1:CAS:528: DC%2BC3cXmslWlsro%3D
138. AM Cypess 2009 Identification and importance of brown adipose tissue in adult humans N Engl J Med 360 1509 1517 19357406 1:CAS:528:DC%2BD1MXltlSqsro%3D
139. WD Marken Lichtenbelt 2009 Cold-activated brown adipose tissue in healthy men N Engl J Med 360 1500 1508 19357405
140. KA Virtanen 2009 Functional brown adipose tissue in healthy adults N Engl J Med 360 1518 1525 19357407 1:CAS:528:DC%2BD1MXltlSqsrs%3D
141. 23-adrenoceptor agonists Naunyn-Schmiedeberg's Arch Pharmacol 378 225 240 1:CAS:528:DC%2BD1cXosVCrsLY%3D (Pubitemid 351977641)
142. G Frühbeck S Becerril N Sáinz P Garrastachu MJ García-Velloso 2009 BAT: a new target for human obesity? Trends Pharmacol Sci 30 387 396 19595466
143. TM Larsen S Toubro MA Van Baak, et al. 2002 Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men Am J Clin Nutr 76 780 788 12324291 1:CAS:528:DC%2BD38Xns1eqsLg%3D
144. LM Redman L De Jonge X Fang, et al. 2007 Lack of an effect of a novel β3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study J Clin Endocrinol Metab 92 527 531 17118998 1:CAS:528:DC%2BD2sXitVaksb4%3D
145. G Bryzgalova 2008 Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141 J Steroid Biochem Mol Biol 111 262 267 18621127 1:CAS:528:DC%2BD1cXhtVamtb%2FE
146. TS Scanlan 2010 Sobetirome: a case history of bench-to-clinic drug discovery and development Heart Fail Rev 15 177 182 19002578
147. CM Villicev 2007 Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats J Endocrinol 193 21 29 17400799 1:CAS:528:DC%2BD2sXlsFSisr4%3D (Pubitemid 46638528)
148. NM Morton 2010 Obesity and corticosteroids: 11[beta]-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease Mol Cell Endocrinol 316 154 164 19804814 1:CAS:528:DC%2BD1MXhs1WgtbnK
149. AR Nawrocki PE Scherer 2005 Keynote review: the adipocyte as a drug discovery target Drug Discov Today 10 1219 1230 16213414 1:CAS:528: DC%2BD2MXhtVGgsLzI (Pubitemid 41411432)
150. M Wang 2007 Glucocorticoid antagonists and 11[beta]-HSD1 inhibitors Drug Discov Today Ther Strat 4 117 122
151. M Wamil JR Seckl 2007 Inhibition of 11-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target Drug Discov Today 12 504 520 17631244 1:CAS:528:DC%2BD2sXnslWlur0%3D (Pubitemid 47031664)
152. Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol. 2010 (In Press). doi: 10.1016/j.jsbmb.2010.03.060.
153. MM Véniant C Hale RW Hungate, et al. 2010 Discovery of a potent, orally active 11Î2-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S, 2S, 4 R)-Bicyclo[2.2.1]heptan-2- ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221) J Med Chem 53 4481 4487 20465278
154. C Fotsch M Wang 2008 Blockade of glucocorticoid excess at the tissue level: inhibitors of 11β-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes J Med Chem 51 4851 4857 18652443 1:CAS:528: DC%2BD1cXovVOhs7c%3D
155. X Su F Pradaux-Caggiano MP Thomas, et al. 2010 Discovery of adamantyl ethanone derivatives as potent 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors ChemMedChem 5 1026 1044 20486152 1:CAS:528: DC%2BC3cXotVOmtL8%3D
156. A Tiwari 2010 INCB-13739, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes IDrugs 13 266 275 20373256 1:CAS:528:DC%2BC3cXpt1yltrc%3D
157. JA Baur 2010 Biochemical effects of SIRT1 activators Biochim Biophys Acta: Proteins Proteomics 1804 1626 1634 1:CAS:528:DC%2BC3cXntlaltb8%3D
158. W-J Jiang 2008 Sirtuins: novel targets for metabolic disease in drug development Biochem Biophys Res Commun 373 341 344 18577374 1:CAS:528: DC%2BD1cXoslGmtbw%3D
159. JC Milne PD Lambert S Schenk, et al. 2007 Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 712 716 18046409 1:CAS:528:DC%2BD2sXhtlKmtbrM (Pubitemid 350207685)
160. JE Bemis CB Vu R Xie, et al. 2009 Discovery of oxazolo[4, 5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators Bioorg Med Chem Lett 19 2350 2353 19303289 1:CAS:528:DC%2BD1MXkt1Sjtbc%3D
161. JN Feige 2008 Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation Cell Metab 8 347 358 19046567 1:CAS:528:DC%2BD1cXhtlOgur7O
162. Sitris Pharmaceuticals. Sirtris development pipeline. Accessed August 15th 2010. http://www.sirtrispharma.com/pipeline.html.
163. M Pacholec JE Bleasdale B Chrunyk, et al. 2010 SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J Biol Chem 285 8340 8351 20061378 1:CAS:528:DC%2BC3cXisl2jtr0%3D
164. G van Boekel S Loves A van Sorge J Ruinemans-Koerts T Rijnders H de Boer 2008 Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression Diab Obes Metab 10 1195 1203
165. A Due A Flint G Eriksen, et al. 2007 No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet Diab Obes Metab 9 566 574 1:CAS:528: DC%2BD2sXosF2ltL4%3D (Pubitemid 47018520)
166. MA Rupnick D Panigrahy CY Zhang, et al. 2002 Adipose tissue mass can be regulated through the vasculature Proc Natl Acad Sci USA 99 10730 10735 12149466 1:CAS:528:DC%2BD38Xmt1Cht74%3D
167. Y Cao 2010 Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases Nat Rev Drug Discov 9 107 115 20118961 1:CAS:528:DC%2BC3cXht1ynsL4%3D
168. ML Reitman 2004 Magic bullets melt fat Nat Med 10 581 582 15170200 1:CAS:528:DC%2BD2cXksVaju7k%3D (Pubitemid 38796844)
169. MG Kolonin PK Saha L Chan R Pasqualini W Arap 2004 Reversal of obesity by targeted ablation of adipose tissue Nat Med 10 625 632 15133506 1:CAS:528:DC%2BD2cXksVaisrY%3D (Pubitemid 38796854)
170. Y Cao 2007 Angiogenesis modulates adipogenesis and obesity J Clin Invest 117 2362 2368 17786229 1:CAS:528:DC%2BD2sXhtVCms7rM (Pubitemid 47494333)
171. A Tiwari P Maiti 2009 TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders Drug Discov Today 14 523 530 19429513 1:CAS:528:DC%2BD1MXltlKqsr0%3D
172. M Watanabe 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 439 484 489 16400329 1:CAS:528:DC%2BD28XntFWmuw%3D%3D (Pubitemid 43152840)
173. C Thomas A Gioiello L Noriega, et al. 2009 TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab 10 167 177 19723493 1:CAS:528:DC%2BD1MXhsVChtLnM
174. R Pellicciari A Gioiello A Macchiarulo, et al. 2009 Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity J Med Chem 52 7958 7961 20014870 1:CAS:528:DC%2BD1MXhsVSgtL%2FE